

## Advanced cancer and concomitant dementia: access to specialized palliative care, emergency room, hospital care, and place of death

Per Fürst<sup>a,b</sup> , Peter Strang<sup>a,b,c</sup>, Christel Hedman<sup>b,d,e</sup>  and Torbjörn Schultz<sup>b</sup>

<sup>a</sup>Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden; <sup>b</sup>Palliative Medicine, Stockholms Sjukhem Foundation, Stockholm, Sweden; <sup>c</sup>Regional Cancer Centre in Stockholm, Gotland, Sweden; <sup>d</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; <sup>e</sup>Department of Clinical Sciences Lund, Division of Palliative Care, Lund University, Lund, Sweden

### ABSTRACT

**Background:** Dementia and advanced cancer are complex, life-limiting conditions that benefit from specialized palliative care (SPC) interventions at the end of life. The objective was to study possible differences in care for patients with concomitant advanced cancer and dementia (CA-DEM) or cancer only (CA) regarding access to SPC, acute hospital care, and place of death.

**Materials and methods:** A retrospective observational registry study on health care consumption data from the Stockholm Regional Council involving logistic regression analyses of age, sex, living arrangements, comorbidities, dementia diagnosis, and socio-economic status.

**Results:** Of the 12,667 persons aged  $\geq 65$  years who died from advanced cancer between 2015 and 2019, 605 had concomitant dementia. Of these, 76% of patients with CA and 42% of patients with CA-DEM had access to SPC ( $p < .0001$ ). There were more admissions to palliative care for persons not living in nursing homes ( $p < .0001$ ), women ( $p < .0001$ ), socioeconomically privileged patients ( $p < .05$ ), those with fewer comorbidities ( $p < .0001$ ), and younger patients ( $< 85$  years) ( $p < .0001$ ). Access to SPC reduced ER visits, hospitalizations, and acute hospital deaths for CA, whereas access to SPC only reduced hospital deaths in the CA-DEM group.

**Conclusions:** The probability of being admitted to SPC was lower in cancer patients with known dementia. Access to SPC reduced emergency room visits and acute admissions to hospitals for the whole group, and hospital deaths both for CA and CA-DEM.

**Abbreviations:** BPSD: behavioral and psychological symptoms in dementia; CA: patients with cancer; CA-DEM: patients with cancer and concomitant dementia; CCI: Charlson Comorbidity Index; EOL: end-of-life; ER: emergency room; ICD: International Classification of Diseases; n.s.: not significant; OR: odds ratio; SPC: specialized palliative care; STROBE: strengthening the reporting of observational studies

### ARTICLE HISTORY

Received 6 October 2021  
Accepted 2 April 2022

### KEYWORDS

Cancer; dementia; palliative care; place of death

### Background

Dementia is a progressive, life-limiting condition. As both dementia and cancer prevalence increase with increasing age, a number of cancer patients will have concomitant dementia, although the incidence of Alzheimer's disease seems somewhat lower in cancer patients, compared to the general public, for unclear reasons [1,2].

At the end-of-life (EOL), people with dementia suffer from neuropsychiatric symptoms, often referred to as behavioral and psychological symptoms in dementia (BPSD), eating problems including dysphagia, infections, breathlessness, and pain [3]. As reviewed by Katrien Moens et al., also other symptoms such as constipation, nausea, fatigue, anxiety, and depression occur in varying frequencies [4]. In parallel, their cognitive decline hampers communication, including assessment of symptoms. In summary, people with dementia have palliative care needs similar to those with malignant diseases [3,4], and for dementia patients who have access to hospice,

the quality of care, as well as quality of dying, seem to be improved [5]. However, most persons with dementia are less likely to be referred to specialist palliative care [6,7].

In contrast, palliative care has gained growing acceptance in oncology for more than five decades [8–10]. Access to palliative care for cancer patients is known to reduce hospital care and is considered a factor for improved symptom control and quality of life [11–13]. There is also increasing evidence that the early introduction of palliative care may be beneficial to patients' quality of life and the distress of their next of kin [10,14,15].

In Sweden, attempts have been made to increase awareness of the benefits of palliative care strategies in end-of-life (EOL) situations, regardless of diagnosis or care location [16,17]. Acute hospitals, but also nursing homes, which usually have round-the-clock access to nurses and doctors on a consulting basis, are expected to provide general palliative care when needed. In outpatient settings, general palliative home care is offered by primary care and is staffed mainly

**CONTACT** Per Fürst  [per.furst@ki.se](mailto:per.furst@ki.se)  Stockholms Sjukhem Foundation's R&D (FoUU), P.O. Box 12230, Stockholm 102 26, Sweden

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group  
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

by district nurses, supported by general practitioners, during office hours.

For individual patients with more complex symptoms and greater needs, specialized palliative care (SPC) is offered, mainly in the form of advanced palliative home care, or in the form of hospital palliative inpatient care. Both types of care are staffed by physicians, registered nurses, physiotherapists, occupational therapists, dietitians, and others, of which physicians and nurses are available around the clock [18]. Specialized palliative consulting teams that support hospitals or nursing homes are, however, lacking in the Stockholm region.

In patients with a combination of both cancer and dementia diagnoses, findings indicate a lower likelihood of active diagnostics and cancer treatment with curative intent [6,19], as well as poorer cancer-related clinical outcomes, including late diagnosis and higher mortality rates, despite greater use of health services [6,20]. In EOL, these individuals obviously have palliative care needs, but we do not know to what extent they are referred to SPC. To the best of our knowledge, there are no studies on whether affiliation to SPC differs between patients with cancer and those with both cancer and dementia, and whether a difference in affiliation would entail differences in equality of care, where emergency room visits, hospital admissions, and place-of-death could be seen as proxies for this. Therefore, our research question was to investigate whether patients with cancer and concomitant dementia gained access to SPC to the same extent as patients with cancer and how their SPC affiliation then affected their care.

### **Aims**

Our aim was to retrospectively compare two groups of  $\geq 65$  years old deceased patients with cancer and patients with concomitant cancer and dementia at EOL regarding their access to SPC. Secondary aims were to study their emergency room visits, hospital admissions, and place of death.

### **Materials and methods**

The methods and results are, when possible, reported based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria [21].

#### **Study design**

We conducted a retrospective observational registry data study based on the VAL, the Stockholm Region's central data warehouse. Data were collected for those who died during the 5 consecutive years, 2015–2019. Various aspects of healthcare consumption were compared between those who died from cancer and those with cancer in combination with dementia. The data were analyzed in relation to age, sex, living arrangements (residents in nursing homes versus all others), comorbidities, dementia diagnosis, and socio-economic status by means of Mosaic. Mosaic is a system that

divides a county or a city into small socio-economic areas (Mosaic groups 1–3), where Mosaic group 1 corresponds to the most affluent areas [22–24].

#### **Population**

All patients over the age of 65 years who had died between 2015 and 2019 with a diagnosis of advanced cancer were included. The age limit of 65 years was chosen to make the groups (cancer only versus cancer with concomitant dementia) more comparable, as cancer deaths are common below the age of 65 years, whereas dementia diagnoses are few. Advanced cancer was defined as either metastasized disease or diagnoses of malignant brain tumors, hematological malignancies, or pancreatic cancer. This was done because brain tumors and hematological malignancies in most cases lack a code for secondary tumors in the International Classification of Diseases (ICD-10), due to their patterns of spread. Pancreatic cancer was included with or without a secondary diagnosis, as the prognosis is very poor, and secondary diagnoses are not always registered in the case records, especially in nursing homes (empirical observation).

#### **Variables**

Access to SPC during the last 3 months of life and emergency room visits, admission to acute hospitals during the last month of life, and death in acute hospitals were used as outcome measures. Geriatric clinics located in acute hospitals or in separate geriatric hospitals were not counted as acute hospitals. As explanatory variables, age, sex, living arrangements (nursing home residents versus all others), Charlson Comorbidity Index (CCI), dementia diagnoses, and Mosaic groups were used. All the included patients had advanced cancer; therefore, this was not added to the CCI index. The CCI is a method of categorizing comorbidities of patients based on the ICD-10 diagnosis codes found in administrative data and is often used as a proxy for comorbidity burden [25]. Mosaic provides socio-economic information, and based on this, the council can define and allocate different areas of residence to three different socio-economic classes (Mosaic 1–3). This is mainly based on income, education, and cultural aspects, lifestyle, and living arrangements. The county of Stockholm is divided into 1300 small areas, and each area is classified as Mosaic 1, 2, or 3. The three groups are approximately equal in size.

#### **Selection bias**

##### **Dropouts**

As reporting of data to VAL is mandatory for each clinic/care unit, data are complete, and very few values are missing. Each person who has used public health care during the study years is included in the VAL database, which also includes most forms of private care, as private care providers have economic agreements with the regional council.

### Nursing home residents

To identify nursing home residents, registrations of medical interventions by doctors were identified. There are exclusive codes for physician care in nursing homes. It is unlikely that a resident living in a nursing home would not have a single registration during the last year of life. If so, they were not included in the study.

### Charlson Comorbidity Index

The nature of VAL ensures that the comorbid conditions relevant to the index are considered, and the risk of missing individuals is considered negligible.

### Study size

The study included all deaths from cancer during 2015–2019. Therefore, no power calculations were performed.

### Statistical methods, missing data

t-Tests and chi-square tests were used to compare the proportions. There were few missing data (mainly the Mosaic classification, in 88 patients), and they were, therefore, not substituted. Initially, univariable logistic regression analyses were performed for relevant variables, which were then entered into multivariable stepwise logistic regression models, with a forward selection. The SAS 9.4/Enterprise guide 8.2 was used for statistical analysis.

### Ethics

The study was approved by the Regional Ethical Review Authority (EPN 2017/1141-31).

### Results

During 2015–2019, there were 12,667 persons aged 65 years or older who died of advanced cancer in Stockholm County. Of these, 12,062 had cancer only (CA) and 605 had both cancer and dementia (CA-DEM). Patients with CA-DEM were older, with a mean age of 83 years, compared to 77 years for CA patients ( $p < .0001$ ). 49% of CA patients were women, and the corresponding figure was 53% for CA-DEM patients

( $\chi^2 = 183$ ,  $p < .0001$ ). 11% of CA and 54% of CA-DEM patients lived in nursing homes. See Table 1 for further characteristics of the main study group.

### Access to specialized palliative care

During the last 3 months of life, 76% of CA and 42% of CA-DEM patients had access to SPC ( $\chi^2 = 367$ ,  $p < .0001$ ) (Table 1). In an initial univariable analysis, the likelihood of being admitted to SPC services during the last 3 months of life was significantly lower for persons with dementia, but higher for women, persons belonging to higher socioeconomic classes (Mosaic 1 and 2), younger age, and patients with fewer comorbidities. The greatest difference was related to residency in a nursing home: patients who were nursing home residents had an OR of only 0.13 to have access to SPC (Table 2). When introduced in a multivariable model that included the same explanatory variables, all significant associations remained significant, although some were weakened (Table 2).

### Emergency room (ER) visits during the last month of life

During the last month of life, 5027 of the patients in the main study group made at least one emergency room visit. A concomitant dementia diagnosis did not affect the likelihood of ER visits (Table 1). In the univariable analysis, the likelihood of visiting an ER was significantly lower for women, persons in the highest socio-economic group, younger persons, persons with few comorbidities, and those with access to palliative care or living in a nursing home (Table 3). In the multivariable model, the associations were confirmed, except for age.

### Admissions to acute hospitals during the last month of life

In multivariable analysis, the figures for admissions to emergency hospitals during the last month of life were similar to the figures for emergency room visits, except for younger age, which meant an increased probability of admission (Table 4). No significant difference was observed between

**Table 1.** Characteristics and care utilization of patients  $\geq 65$  years of age dying with advanced cancer<sup>a</sup> in Stockholm County 2015–2019.

	Patients with advanced cancer and dementia (CA-DEM)	Patients with advanced cancer only (CA)	Total	p-Value
Deaths, <i>n</i>	605	12,062	12,667	
Women (%)	319 (53)	5867 (49)	6186 (49)	<.0001
Age, all, years, mean (SD)	82.9 (7)	77.2 (8)	77.5 (8)	<.0001
Women	83.4 (7)	77.4 (8)	77.7 (8)	<.0001
Men	82.4 (6)	77.1 (8)	77.4 (8)	<.0001
Care in nursing homes (%)	325 (54)	1358 (11)	1683 (13)	<.0001
Age, nursing home residents, years, mean (SD)	83.8 (7)	82.2 (8)	82.5 (8)	<.0001
Access to SPC, <i>n</i> (%)	253 (42)	9193 (76)	9446 (75)	<.0001
ER visits last month of life (%)	259 (43)	4768 (40)	5027 (40)	.11
Acute hospital admissions last month of life (%)	259 (43)	5575 (46)	5834 (46)	.10
Place-of-death: acute hospitals (%)	81 (13)	1910 (16)	1991 (15)	.11

CA: patients with cancer; CA-DEM: patients with cancer and concomitant dementia.

<sup>a</sup>Advanced cancer; patients with a metastasized disease, diagnosis of pancreatic, brain or hematological cancer.

**Table 2.** Access to specialized palliative care.

	Univariable analysis		Multivariable analysis	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Sex				
Female	1.23 (1.13–1.33)	<.0001	1.28 (1.18–1.40)	<.0001
Male	Ref.		Ref.	
Socioeconomic status				
Mosaic group 1	1.17 (1.05–1.30)	.003	1.15 (1.03–1.29)	.02
Mosaic group 2	1.17 (1.07–1.29)	.001	1.12 (1.01–1.24)	.03
Mosaic group 3	Ref.		Ref.	
Age group				
65–74 years	2.61 (2.35–2.90)	<.0001	1.59 (1.42–1.79)	<.0001
75–84 years	1.93 (1.74–2.14)	<.0001	1.43 (1.28–1.61)	<.0001
85 years or older	Ref.		Ref.	
Charlson Comorbidity Index				
0–1	1.78 (1.64–1.93)	<.0001	1.42 (1.29–1.55)	<.0001
2 or more	Ref.		Ref.	
Nursing home				
Residency	0.13 (0.12–0.15)	<.0001	0.17 (0.15–0.19)	<.0001
Non-residency	Ref.		Ref.	
Concomitant dementia diagnosis				
Yes	0.22 (0.19–0.26)	<.0001	0.5 (0.41–0.60)	<.0001
No	Ref.		Ref.	

Odds ratio (OR) of the probability of having access to specialized palliative care for patients  $\geq 65$  years of age dying with advanced cancer<sup>a</sup> in Stockholm County 2015–2019.

The analyses are based on 12,579 cases, as there were missing data on 88 patients with regards to the Mosaic group.

Ref.: Reference.

<sup>a</sup>Advanced cancer; patients with a metastasized disease, diagnosis of pancreatic, brain or hematological cancer.

the CA and CA-DEM groups, or between different Mosaic groups.

### Hospitals as the place of death

In the multivariable analysis, access to palliative care, living in a nursing home but also female sex, having fewer comorbidities (CCI), as well a dementia diagnosis, were associated with a lower probability of having an acute hospital as a place of death, whereas lower age was associated with a higher probability (Table 5).

### CA-DEM: subgroup analyses

As CA-DEM was our group of special interest, additional analyses were made between those with and without access to SPC. SPC did not influence ER visits or acute hospitalizations during the last month of life but affected place of death: Among those with and without access to SPC, there were 3 and 21%, respectively of hospital deaths ( $p < .0001$ , Table 6).

### Discussion

In summary, CA had access to SPC almost twice as often as CA-DEM, despite similar advanced cancer trajectories. Moreover, admission to SPC was more probable for women, younger patients, those from more affluent socioeconomic areas, patients with fewer comorbidities, and those with ordinary living arrangements. For the whole group (CA + CA-DEM), access to SPC reduced ER visits, hospitalizations, and

**Table 3.** Emergency room visits.

	Univariable analysis		Multivariable analysis	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Sex				
Female	0.85 (0.79–0.91)	<.0001	0.91 (0.85–0.98)	.02
Male	Ref.		Ref.	
Socioeconomic status				
Mosaic group 1	0.86 (0.78–0.94)	.0012	0.89 (0.81–0.98)	.013
Mosaic group 2	0.92 (0.84–1.00)	.047	0.95 (0.87–1.03)	.23
Mosaic group 3	Ref.		Ref.	
Age group				
65–74 years	0.86 (0.78–0.94)	.0013	ns.	ns.
75–84 years	0.91 (0.83–1.00)	.054		
85 years or older	Ref.			
Charlson Comorbidity Index				
0–1	0.65 (0.60–0.70)	<.0001	0.68 (0.63–0.74)	<.0001
2 or more	Ref.		Ref.	
Nursing home				
Residency	0.79 (0.71–0.88)	<.0001	0.46 (0.41–0.52)	<.0001
Non-residency	Ref.		Ref.	
Access to palliative care				
Yes	0.44 (0.40–0.48)	<.0001	0.37 (0.34–0.41)	<.0001
No	Ref.		Ref.	
Concomitant dementia diagnosis				
Yes	1.15 (0.97–1.35)	.11	ns.	ns.
No	Ref.			

Odds ratio (OR) for the probability of patients,  $\geq 65$  years dying with advanced cancer<sup>a</sup> in Stockholm County 2015–2019, to visit an emergency room (ER) at an acute hospital during the last month of life.

The analyses are based on 12,579 cases, as there were missing data on 88 patients with regards to the Mosaic group, of these 5027 had ER visits.

ns.: not significant; Ref.: reference.

<sup>a</sup>Advanced cancer; patients with a metastasized disease, diagnosis of pancreatic, brain or hematological cancer.

**Table 4.** Admissions to acute hospital.

	Univariable analysis		Multivariable analysis	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Sex				
Female	0.86 (0.81–0.93)	<.0001	0.93 (0.87–1.00)	.047
Male	Ref.		Ref.	
Socioeconomic status				
Mosaic group 1	0.96 (0.88–1.01)	.43	ns.	ns.
Mosaic group 2	0.91 (0.84–0.99)	.03		
Mosaic group 3	Ref.			
Age group				
65–74 years	1.33 (1.21–1.47)	<.0001	1.39 (1.26–1.54)	<.0001
75–84 years	1.20 (1.10–1.32)	.0002	1.21 (1.10–1.34)	.0001
85 years or older	Ref.		Ref.	
Charlson Comorbidity Index				
0–1	0.70 (0.65–0.75)	<.0001	0.69 (0.64–0.75)	<.0001
2 or more	Ref.		Ref.	
Nursing home				
Residency	0.61 (0.55–0.68)	<.0001	0.41 (0.37–0.47)	<.0001
Non-residency	Ref.		Ref.	
Access to palliative care				
Yes	0.55 (0.50–0.59)	<.0001	0.42 (0.38–0.46)	<.0001
No	Ref.		Ref.	
Dementia diagnosis				
Yes	0.87 (0.74–1.03)	.10	ns.	ns.
No	Ref.			

Odds ratio (OR) for the probability of patients,  $\geq 65$  years of age dying with advanced cancer<sup>a</sup> in Stockholm County 2015–2019, to be admitted to an acute hospital in Stockholm County during the last month of life.

The analyses are based on 12,579 cases, as there were missing data on 88 patients with regards to the Mosaic group.

ns.: not significant; Ref.: reference.

<sup>a</sup>Advanced cancer; patients with a metastasized disease, diagnosis of pancreatic, brain or hematological cancer.



**Table 5.** Place of death.

	Univariable analysis		Multivariable analysis	
	OR (95% CI)	p-value	OR (95% CI)	p-value
Sex				
Female	0.71 (0.64–0.78)	<.0001	0.82 (0.73–0.92)	.0007
Male	Ref.		Ref.	
Socioeconomic status				
Mosaic group 1	0.85 (0.75–0.96)	.009	ns.	ns.
Mosaic group 2	0.84 (0.75–0.94)	.002		
Mosaic group 3	Ref.			
Age group				
65–74 years	1.49 (1.30–1.70)	<.0001	2.29 (1.94–2.70)	<.0001
75–84 years	1.27 (1.11–1.46)	.0007	1.62 (1.38–1.91)	<.0001
85 years or older	Ref.		Ref.	
Charlson Comorbidity Index				
0–1	0.61 (0.55–0.67)	<.0001	0.65 (0.58–0.74)	<.0001
2 or more	Ref.		Ref.	
Nursing home				
Residency	0.59 (0.50–0.69)	<.0001	0.17 (0.14–0.20)	<.0001
Non-residency	Ref.		Ref.	
Access to palliative care				
Yes	0.09 (0.08–0.10)	<.0001	0.05 (0.04–0.06)	<.0001
No	Ref.		Ref.	
Concomitant dementia diagnosis				
Yes	0.82 (0.65–1.04)	.11	0.66 (0.50–0.88)	.004
No	Ref.		Ref.	

Odds ratio (OR) for the probability of patients,  $\geq 65$  years of age dying with advanced cancer<sup>a</sup> in Stockholm County 2015–2019, to have an acute hospital as a place of death.

The analyses are based on 12,579 cases, as there were missing data on 88 patients with regards to the Mosaic group.

ns.: not significant; Ref.: reference.

<sup>a</sup>Advanced cancer; patients with a metastasized disease, diagnosis of pancreatic, brain or hematological cancer.

**Table 6.** Subgroup analysis of hospital care consumption for CA-DEM, between those with and without access to SPC ( $n = 601$ ).

Hospital utilization	CA-DEM with SPC $n = 253$	CA-DEM without SPC $n = 348$	p-Value
ER visits last month (%)	106 (42)	153 (44)	.61 (ns.)
Hospitalizations last month (%)	117 (46)	142 (41)	.18 (ns.)
Hospitals as place-of death (%)	8 (3)	73 (21)	<.0001

CA: patients with cancer; CA-DEM: patients with cancer and concomitant dementia; ns.: not significant.

hospital deaths, whereas access to SPC for the subgroup of CA-DEM only reduced the probability to die in acute hospitals.

This is of interest as studies have shown that most patients with advanced diseases prefer to die in their homes, especially if offered access to specialized palliative care [26–29]. In our study, the probability of having an acute hospital as place-of-death was low for both groups, 13% for CA-DEM and 16% for CA, which is probably explained by the fact that CA-DEM persons were cared for to a great extent in nursing homes, whereas CA patients often were admitted to SPC, two variables that reduce hospital consumption, in general. As shown, acute hospital deaths were less likely for those with access to SPC, both in the CA and in the CA-DEM group.

The proportion of persons with dementia was 4.8%, which is lower than for the general population with figures of about 8%, but in good agreement, for example, with a study on breast cancer where a figure of 4.6% of dementia was reported [30,31]. This is partly explained by a lower mean

age in dying cancer patients, in our study 77.5 years, compared with the average age at death which is 82.5 years in Sweden [32]. As a further explanation, the risk of Alzheimer's disease has been reported to be reduced in cancer patients compared to cancer-free controls [1,2,33].

In our study, the probability of obtaining SPC was lower for CA-DEM. This may be a disadvantage as patients with advanced cancer are likely to have complex palliative care needs, which are preferably handled by staff with expert knowledge of symptom control. Exactly to what extent SPC also masters combined diseases varies and the results from studies on palliative care in dementia cannot be easily transferred to the group of patients who also have very advanced cancer, not least regarding end-of-life trajectories [34]. Still, the fact that patients with combined diagnoses have less access to SPC can be considered a marker of unequal access to an adequate level of care, as we only included cancer patients with metastatic disease in both groups, and patients with disseminated cancer are known to have complex symptoms.

Patients with CA-DEM can be expected to have different palliative care needs than patients with dementia only, and neither group does really fit into the SPC offered in the Stockholm region today, as SPC is mainly designed for cognitively intact persons. Staff in SPC generally lack training in dementia care, whereas nursing homes are mainly staffed by assistant nurses with more appropriate training in dementia care, but nursing homes do not have adequate medical staffing for more complex symptom control. Moreover, Stockholm region has no system for SPC consultations in nursing homes.

This should be an incitement to train staff in nursing homes in palliative care issues, as some of these patients probably prefer to stay in their well-known environment but need knowledgeable palliative care [7,35–38]. Another possible solution would be the development of a new type of palliative care, for example in the form of consulting. This would imply that, when needed, specialized palliative home care teams or specialized palliative geriatric care services could be consulted. In this way, the residents would both receive knowledgeable dementia care and palliative care expertise, when needed.

### Strengths and limitations

As reporting to the VAL databases is mandatory and includes all ICD-10 diagnoses from hospitals, outpatient, and primary care, there are a few missing values which is a strength. The chosen period, 2015–2019, means that the results are up to date and are still not affected by the COVID-19 pandemic, which started in 2020.

A limitation of this study is that the patients were identified by their main diagnosis (cancer and/or dementia) and secondary diagnoses (metastases), but we did not have access to actual death certificates. Therefore, the immediate cause of death may have been conditions other than advanced cancer in a few cases.

A possible confounder is that CA-DEM to a high degree were cared for in nursing homes, which affects the probability of ER visits and hospital admissions. Patients with dementia in the Stockholm region may be followed by a specialized dementia clinic during the first year after diagnosis whereafter both dementia patients living at home and in nursing homes are cared for primarily by the primary care's general palliative care and with nursing interventions *via* the local municipality.

## Conclusions

In conclusion, access to SPC was better for patients with advanced cancer than for those with concomitant dementia. Access to SPC reduced emergency room visits and admissions to acute hospitals, for the whole group, but this was not seen for the subgroup of CA-DEM. SPC was associated with fewer hospital deaths for both groups.

Increased access to palliative care for staff in nursing homes, for example in the form of interventions by palliative consulting teams, could probably improve palliative care for the vulnerable group of patients with cancer and concomitant dementia.

## Acknowledgments

We are grateful to the Stockholm Region for providing data for this study. Stockholms Sjukhem is acknowledged for providing facilities for research. Helena Adlitzter at Regional Cancer Centre Stockholm-Gotland is acknowledged for valuable discussions during the planning of the study. Editage ([www.editage.com](http://www.editage.com)) is acknowledged for linguistic revision.

## Disclosure statement

No potential conflict of interest was reported by the author(s).

## Funding

Dr. Strang reports receiving grants from the RCC, Regional Cancer Center Stockholm-Gotland (Dnr VKN 2019-0070), the Cancer Research Funds of Radiumhemmet (no. 201241), Region Stockholm (ALF project 20200472), and Stockholms Sjukhem Foundation's Jubilee Fund during the conduct of the study.

## ORCID

Per Fürst  <http://orcid.org/0000-0001-5363-833X>  
Christel Hedman  <http://orcid.org/0000-0003-4183-7598>

## Data availability statement

The data that support the findings of this study are available from the corresponding author, [PF], upon reasonable request.

## References

- [1] Ma LL, Yu JT, Wang HF, et al. Association between cancer and Alzheimer's disease: systematic review and meta-analysis. *JAD*. 2014;42(2):565–573.
- [2] Shi HB, Tang B, Liu YW, et al. Erratum to: Alzheimer disease and cancer risk: a meta-analysis. *J Cancer Res Clin Oncol*. 2015; 141(3):571.
- [3] Eisenmann Y, Golla H, Schmidt H, et al. Palliative care in advanced dementia. *Front Psychiatry*. 2020;11:699.
- [4] Moens K, Higginson IJ, Harding R, Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. *J Pain Symptom Manage*. 2014;48(4):660–677.
- [5] Teno JM, Gozalo PL, Lee IC, et al. Does hospice improve quality of care for persons dying from dementia? *J Am Geriatr Soc*. 2011; 59(8):1531–1536.
- [6] McWilliams L, Farrell C, Grande G, et al. A systematic review of the prevalence of comorbid cancer and dementia and its implications for cancer-related care. *Aging Ment Health*. 2018;22(10): 1254–1271.
- [7] Afzal N, Buhagiar K, Flood J, et al. Quality of end-of-life care for dementia patients during acute hospital admission: a retrospective study in Ireland. *Gen Hosp Psychiatry*. 2010;32(2):141–146.
- [8] Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. *Ther Adv Med Oncol*. 2013;5(6):318–323.
- [9] Mathews J, Hannon B, Zimmermann C. Models of integration of specialized palliative care with oncology. *Curr Treat Options Oncol*. 2021;22(5):44.
- [10] Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a lancet oncology commission. *Lancet Oncol*. 2018; 19(11):e588–e653.
- [11] Higginson IJ, Finlay I, Goodwin DM, et al. Do hospital-based palliative teams improve care for patients or families at the end of life? *J Pain Symptom Manage*. 2002;23(2):96–106.
- [12] Bajwah S, Oluyase AO, Yi D, et al. The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers. *Cochrane Database Syst Rev*. 2020;9(9):CD012780.
- [13] Strang P, Fürst P, Hedman C, et al. Chronic obstructive pulmonary disease and lung cancer: access to palliative care, emergency room visits and hospital deaths. *BMC Pulm Med*. 2021;21(1):170.
- [14] Ambroggi M, Biasini C, Toscani I, et al. Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. *Support Care Cancer*. 2018;26(9):2945–2953.
- [15] Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. *JAMA*. 2009;302(7):741–749.
- [16] SOU 2001:6. Döden angår oss alla - värdig vård vid livets slut. [cited 2021 Sep 27]. Available from: [https://www.riksdagen.se/sv/dokument-lagar/dokument/statens-offentliga-utredningar/sou-2001-6-\\_GPB36](https://www.riksdagen.se/sv/dokument-lagar/dokument/statens-offentliga-utredningar/sou-2001-6-_GPB36).
- [17] Socialstyrelsen – The Swedish National Board of Health and Welfare. End of life palliative care - National guidelines. [cited 2021 Sep 27]. Available from: [www.socialstyrelsen.se](http://www.socialstyrelsen.se).
- [18] Nordström M, Strang P. High degree of satisfaction with the support given by multidisciplinary palliative home care teams in the county of Stockholm. *J Palliat Care*. 2018;33(2):109–114.
- [19] Morin L, Beaussant Y, Aubry R, et al. Aggressiveness of end-of-life care for hospitalized individuals with cancer with and without dementia: a nationwide matched-cohort study in France. *J Am Geriatr Soc*. 2016;64(9):1851–1857.
- [20] McWilliams L. An overview of treating people with comorbid dementia: implications for cancer care. *Clin Oncol*. 2020;32(9): 562–568.

- [21] Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology*. 2007;18(6):805–835.
- [22] InsightOne. Experia MIS Mosaic™ Sweden. Available from: <https://insightone.se/mosaic/>.
- [23] Dahlén E, Komen J, Jonsson EW, et al. Eliminated patient fee and changes in dispensing patterns of asthma medication in children—an interrupted time series analysis. *Basic Clin Pharmacol Toxicol*. 2019;125(4):360–369.
- [24] Strang P, Furst P, Schultz T. Excess deaths from COVID-19 correlate with age and socio-economic status. A database study in the Stockholm region. *Ups J Med Sci*. 2020;125(4):297–304.
- [25] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–383.
- [26] Higginson IJ, Daveson BA, Morrison RS, et al. Social and clinical determinants of preferences and their achievement at the end of life: prospective cohort study of older adults receiving palliative care in three countries. *BMC Geriatr*. 2017;17(1):271.
- [27] Cohen J, Pivodic L, Miccinesi G, et al. International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data. *Br J Cancer*. 2015;113(9):1397–1404.
- [28] Gomes B, Calanzani N, Gysels M, et al. Heterogeneity and changes in preferences for dying at home: a systematic review. *BMC Palliat Care*. 2013;12:7.
- [29] Ali M, Capel M, Jones G, et al. The importance of identifying preferred place of death. *BMJ Support Palliat Care*. 2019;9(1):84–91.
- [30] Alzheimer Europe. The prevalence of dementia in Europe 2014. Alzheimer Europe, Luxembourg; 2014 [cited 2021 May 10]. Available from: <https://www.alzheimer-europe.org/Policy/Country-comparisons/2013-The-prevalence-of-dementia-in-Europe/Sweden>.
- [31] Kiderlen M, de Glas NA, Bastiaannet E, et al. Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study. *Breast Cancer Res Treat*. 2014;145(1):185–192.
- [32] Statistics Sweden. Medellivslängden i Sverige. Statistics Sweden, Örebro; 2021 [cited 2022 January 13]. Available from: <https://www.scb.se/hitta-statistik/sverige-i-siffror/manniskorna-i-sverige/medellivslangd-i-sverige/>.
- [33] Sun M, Wang Y, Sundquist J, et al. The association between cancer and dementia: a national cohort study in Sweden. *Front Oncol*. 2020;10:73.
- [34] Murray SA, Kendall M, Boyd K, et al. Illness trajectories and palliative care. *BMJ*. 2005;330(7498):1007–1011.
- [35] Murphy E, Froggatt K, Connolly S, et al. Palliative care interventions in advanced dementia. *Cochrane Database Syst Rev*. 2016;12(12):CD011513.
- [36] Morris DA, Galicia-Castillo M. Caring about residents' experiences and symptoms (CARES) program: a model of palliative care consultation in the nursing Home. *Am J Hosp Palliat Care*. 2017;34(5):466–469.
- [37] Chang E, Daly J, Johnson A, et al. Challenges for professional care of advanced dementia. *Int J Nurs Pract*. 2009;15(1):41–47.
- [38] Bolt SR, van der Steen JT, Schols J, et al. Nursing staff needs in providing palliative care for people with dementia at home or in long-term care facilities: a scoping review. *Int J Nurs Stud*. 2019;96:143–152.